RxDoctor Payments Data

Anhtuan Tran, MD

Internal Medicine · van Nuys, CANPI 1518961846

Payments from drug & device makers

$1,619in general payments, 2019–2025

Across 36 payments — averaging $44.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$608
  • Lilly USA, LLC$315
  • Bayer$267
  • Boehringer Ingelheim$241
  • Penumbra, Inc.$108
  • Merck$32
  • plus $49 from 2 others

What the payments were for

  • Food & beverage$1,59999%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,619 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$92,944
Medicare patients
93
Services billed
801

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol143$142,888
JardianceEmpagliflozin95$76,399
JanuviaSitagliptin Phosphate70$57,797
EliquisApixaban28$25,152
OzempicSemaglutide19$17,303
TradjentaLinagliptin13$13,529
VascepaIcosapent Ethyl25$10,106
KerendiaFinerenone14$9,783
Janumet XrSitagliptin Phos/Metformin Hcl12$6,738
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$6,049
Atorvastatin Calcium604$5,335
Novolog Mix 70-30Insulin Aspart Prot/Insuln Asp13$4,066
Dexlansoprazole DrDexlansoprazole14$3,202
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$3,137
Nifedipine ErNifedipine58$2,862

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$608$142,888143 claims
Boehringer IngelheimJardiance, Tradjenta$241$89,927108 claims
MerckJanuvia, Janumet Xr$32$64,53482 claims
BayerKerendia$267$9,78314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in van Nuys

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →